Rubicon
Research is an IP led CDMO and specialty
pharmaceutical company that leverages proprietary drug delivery technologies,
specialized formulation development skills, and project delivery experience to serve
patients worldwide.
Our portfolio spans pharmaceutical product development
and manufacturing across multiple dosage forms, including oral solids, oral
liquids, sterile injectables, and drug-device combinations. We supply products
to USA, EU, Australia, New Zealand,
Canada, Turkey, and Korea, and are actively looking for partners in Emerging Markets.